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Background: Intentional drug overdose (IDO) is the most common form of hospital-treated 
self-harm, yet no study has systematically classified the range of drugs involved using a 
validated system. We aimed to determine the profile of patients engaging in overdose, to 
identify drugs frequently used and to quantify the contributions of multiple drug use and alcohol 
involvement.   
Methods: Between 2012 and 2014, the National Registry of Deliberate Self-Harm, Ireland 
recorded 18,329 presentations of non-fatal intentional drug overdose (IDO) to Irish emergency 
departments. Information on demographic and overdose characteristics were obtained. Drugs 
were categorised using the Anatomical Therapeutic Chemical (ATC) classification system. 
Results: Analgesics (32.4%), antidepressants (21.9%), anxiolytics (21.2%) and hypnotics and 
sedatives (21.0%) were the most frequently used drugs types involved in overdose. 
Presentations involving analgesic and antidepressant medication were more common for 
females whereas males more often took illegal, anxiolytic and hypnotic and sedative drugs. 
Overdoses with drugs other than those which affect the nervous system were identified, 
including musculoskeletal drugs, taken in 12.0% of presentations. Paracetamol was the most 
frequently used drug, particularly among females (32.0%) and persons under 25 years 
(21.7%). Alcohol was most often present in overdoses involving anxiolytics and illegal drugs. 
Multiple drug use was a factor in almost half of presentations.  
Conclusions: People who engage in IDO frequently take prescription only or sales restricted 
drugs, often involving alcohol and/or multiple drug use. These findings highlight the importance 
of addressing drug and alcohol misuse, potential inappropriate prescribing and the 
enforcement of legislation restricting specific drug sales. 





The individual and societal impact of non-fatal intentional drug overdose (IDO) is significant. 
Its association with morbidity, repeat self-harm and suicide is well established (1-4). Intentional 
drug overdose is the most common form of hospital treated self-harm, involved in 65-85% of 
presentations in Oxford, Manchester and Derby as reported by the Multicentre self-harm study 
(5, 6), and in Ireland by the National Self-Harm Registry (7). Most commonly enacted by 
females and by persons aged under 45 years (1), IDO is associated with multiple drug use 
and alcohol consumption (2, 8). Alcohol is involved in between 43-59% of self-harm 
presentations (1, 8, 9) and is of concern due to the increased lethality of IDOs involving alcohol 
(10), its association with complications in medical treatment and the increased risk of long-
term alcohol related death among persons who self-harm involving alcohol (11). 
Psychotropic and analgesic drugs currently represent the most frequently reported drug types 
involved in IDO (1, 2, 12-14). Approximately one-third of IDOs in Ireland entail the use of minor 
tranquillisers (7), whereas paracetamol-containing medication are more common in IDO in 
England, as per the Multicentre study (6, 15). Additionally, benzodiazepines and 
antipsychotics are associated with misuse and frequent use in IDO (16, 17). Multiple drug use 
is an important factor in IDO, involved in 18-26% of presentations, with implications for patient 
treatment, outcome and controlling access to drugs (9, 17).  
Earlier research indicates that the frequency and trends of drugs taken in IDO reflects their 
availability and prescribing in a population (13, 18-21). This association presents an 
opportunity for means restriction interventions, for which a current and comprehensive 
evidence-base regarding drugs used in IDO is essential. Studies conducted to date generally 
apply ad hoc classifications to drugs used in IDO, based on what are assumed to be the most 
common drug groups. This method of classification does not allow for the complete 
examination of all drugs used, resulting in many drugs being represented within a large 
miscellaneous ‘other drugs’ category. Moreover, these classifications often do not include 
drugs other than those that affect the nervous system including, for example, those used to 




standardised classifications also restricts the comparability of information regarding drugs 
used across surveillance systems and registries.  
The Anatomical Therapeutic Chemical (ATC) system is a World Health Organization (WHO) 
recommended classification system designed to measure drug utilisation at an internationally 
comparable level (22). This is the first known study of a national self-harm surveillance system 
to examine drugs taken in IDO according to the ATC system. The application of this system is 
progressive in this area as it will provide an up-to-date, standardised and complete breakdown 
of all drugs used in IDO, necessary to inform suicide and self-harm research, intervention and 
policy, whilst facilitating comparative drug utilisation research between countries and across 
healthcare settings. This national study examines the clinical and socio-demographic profile 
of patients who engage in IDO, detailing drugs used according to their ATC classification with 









2.1. National Self-Harm Registry, Ireland (NSHRI) 
This is a national system that monitors the occurrence of hospital-treated self-harm. Since 
2006 the Registry has collected self-harm data from all 36 acute hospitals across the Republic 




December 31st 2014. Data collection is carried out by trained Data Registration Officers 
(DROs). Cases of self-harm are independently identified and recorded by DROs using a 
combination of manual and electronic checks of emergency department presentations. For a 
full description of data items and procedures of the Registry, please refer to Perry et al., 2012 
(7).  
2.2. Recording of self-harm methods  
Cases of IDO include those with ICD-10 codes of X60-X64 (overdose of drugs and 
medicaments). Presentations of accidental overdose with prescribed medications intended to 
treat specific illnesses or with illegal drugs used for recreational purposes and poisonings of 
undetermined intent (ICD-10 codes Y10-Y19), were not included. Cases involving other 
poisoning agents and alcohol-only self-poisoning cases were excluded. Drug names and 
quantity of tablets ingested, involving up to 13 drugs, are captured via self-reported information 
from the patient, ambulance service records, hospital medical records, and toxicology reports 
where present. Alcohol involvement prior to or during the act of IDO is captured through 
hospital case notes as recorded on registration or by the attending clinician, or if present in 
toxicology reports.  
2.3. Classification of drugs taken in IDO using the Anatomical Therapeutic Chemical (ATC) 
system  
The ATC system categorises  drugs according to the system or organ upon which they act, 
stratifying them according to their chemical, pharmacological and therapeutic properties, the 
detail of which can be found in the Guidelines for ATC Classification (22). An ATC code was 
applied to all drugs examined by the researcher (CD) with validation cross-checks provided 
by a co-author (DMA) who is a qualified pharmacist. Drugs classified within the ATC system 
may be used for two or more equally important indications. Such drugs were attributed one 
code, based on its main indication, as determined by the literature (22). Drugs were classified 




were identified using the Misuse of Drugs Acts (23, 24). In accordance with these Acts, we 
identified illegal drugs as those with no or very little medicinal purposes. For IDOs involving 
intravenous illegal drugs, the quantities taken were recorded as missing. As a result of self-
report, 2,005 (10.9%) of drugs taken were reported as ‘unknown’. For a further 593 (3.2%) of 
drugs recorded the classification of ‘unknown’ was attributed to them as it was not possible to 
apply an ATC code based on limited information available. In the context of this paper, multiple 
drug use refers to the use of two or more drugs other than alcohol involved in a presentation. 
Single drug use refers to the use of just one drug type, other than alcohol, per presentation. 
2.4. Ethical approval and data protection 
The Registry has ethical approval from the National Research Ethics Committee of the Faculty 
of Public Health Medicine. The National Suicide Research Foundation is registered with the 
Data Protection Agency and complies with the Irish Data Protection Act of 1988 and the Irish 
Data Protection (Amendment) Act of 2003. 
2.5. Statistical analysis and reporting 
Statistical analyses were conducted using IBM SPSS version 22.0. We applied a threshold of 
p<0.01 to signify statistical significance. Due to the large sample size in this study many 
outcomes were found to be statistically significant at p<0.05 but overall the magnitude of 
identified differences was small. Where presentation numbers fell below 5 data was not 
published to protect the identity of individuals. The reporting of this study conforms to the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: 



















3.1. Profile of persons engaging in IDO 
During the study period 1st January 2012 to 31st December 2014 there were 18,329 self-harm 
presentations involving IDO, representing 67.6% of all self-harm presentations. The majority 
(58.7%) of presentations were made by females. As described in Table 1, presentations were 
proportionately highest among persons aged 15-24 years (28.3%), and decreased with 
increasing age. The majority of IDO presentations involved overdose only (89.5%) with self-
cutting identified as the most common combined method, involved in 6.5% of IDOs. Alcohol 
was present in 40.6% of IDOs, more common in male presentations (44.7% vs 37.8%, 
x2=86.82, df=1, p<0.01) and highest among those aged 25-34 years (25.1%, x2=619.61, df=5, 




number of total tablets taken per IDO case was 23 for males (IQR: 12-40) and 20 for females 
(IQR: 12-35). Over one-third of presentations involved the ingestion of between 20 and 49 
tablets (36.7%) and 14.0% of presentations involved 50 or more tablets. 
<Table 1 here> 
3.2. Classification of drug types involved in IDO 
Four fifths of IDOs (80.2%) involved drugs affecting the nervous system, with musculoskeletal 
system drugs present in 12.0% of presentations (Table 2). Illegal drugs were involved in 6.0% 
of IDOs. Drugs affecting the alimentary tract and metabolism were involved in 851 
presentations (4.6%) and cardiovascular system drugs were similarly common, in 3.9% of 
presentations. 
<Table 2 here> 
3.3. Nervous system drugs involved in IDO  
The most commonly taken drugs in IDO are described in Table 3. Hypnotic and sedative drugs 
were involved in approximately one fifth (21.0%) of IDOs. Benzodiazepine derivatives were 
involved in over one in three presentations (36.4%). Analgesics were taken in almost one-third 
of IDOs (32.4%). Antidepressants were involved in more than one in five (21.9%) 
presentations. Antiepileptic drugs were involved in 8.9% of IDOs (Table 4), of which the many 
were either pregabalin or gabapentin (49.5%).  
<Table 3 here> 
3.4. Drugs most frequently involved in IDO 
Table 4 illustrates the individual drugs most frequently taken in IDO. Five of these are 
benzodiazepine derivatives and other related drugs (diazepam, zopiclone, alprazolam, 
zolpidem and flurazepam), cumulatively involved in 31.1% of presentations. The most 
frequently used drug was paracetamol, involved in 27.8% of IDOs. Anti-inflammatory drugs 
ibuprofen and diclofenac, and antidepressant drugs escitalopram and venlafaxine were also 




<Table 4 here> 
3.5. Gender and age differences 
Significant gender differences were found in relation to drugs involved in IDO. Musculoskeletal 
system drugs were significantly more common in female compared to male IDOs (14.0% vs 
9.2%, x2=94.34, df=1, p<0.01). Similarly, IDO involving analgesics and antidepressants were 
significantly more common in female presentations (36.4% vs. 26.7%, x2=191.65, df=1, 
p<0.01 and 23.9% vs. 19.1%, x2=59.865, df=1, p<0.01) (Table 3). In particular paracetamol 
was involved significantly more often in female IDOs (32.0% vs 21.7%, x2=232.16, df=1, 
p<0.01). Illegal drugs were three times more common in male compared to female 
presentations (10.1% vs 3.1%, x2=388.66, df=1, p<0.01) (Table 2). Similarly, anxiolytic drugs 
were also taken significantly more frequently by males (24.2% vs 19.2%, x2=68.388, df=1, 
p<0.01).  
 
Regarding age, those under 25 years took analgesic drugs more frequently than those within 
the older age groups (39.9%, x2=206.30, df=2, p<0.01). Paracetamol overdose was highest 
among persons under 25 years (36.2%, x2=292.30, df=2, p<0.01) and was present in 43.8% 
of IDOs by females aged under 25 years. Benzodiazepine involvement increased with age 
and was highest for those aged 45 years and over (44.3%, x2=502.16, df=2, p<0.01). 
Antidepressants were involved most commonly among those aged 45 years and over (24.7%, 
x2=89.17, df=2, p<0.01). Hypnotics and sedative use in IDO was significantly higher among 
those aged 45 years and over (28.9%, x2=438.00, df=2, p<0.01), involving mainly sleeping 
sedatives zopiclone, zolpidem and flurazepam (9.2%, 4.6% and 3.4%). 
 
3.6. Alcohol involvement 
Alcohol involvement in IDO was significantly higher in male compared to female presentations 




presentations involving illegal drugs (47.8%) followed by anxiolytics (49.3%, x2=154.52, df=1, 
p<0.01) (Table 3).  
 
3.7. Multiple versus single drug use     
As described in Table 1 presentations made by those aged 15-24 years had the highest 
proportion of multiple drug use when compared to other age groups (26.3%, x2=74.55, df=5, 
p<0.01). The median number of tablets taken was considerably higher in multiple drug use at 
27 (IQR 15-45) compared to a median of 18 (IQR 10-30) in single drug use (t=25.112, p<0.01). 
Of those who engaged in multiple drug use 59.5% took more than 20 tablets in their IDO 



























4.1. Key findings 
This is the first national study to descriptively profile IDO. The present study utilised a national 
self-harm surveillance system to describe the clinical and socio-demographic profile of 
persons engaging in IDO, to identify drugs used in overdose and to quantify the frequency of 
alcohol involvement and multiple drug use. We found that individuals engaging in IDO were 
most often female and young to middle aged. Alcohol use was particularly associated with 
being male and over 35 years, taken most often in presentations involving anxiolytics and 
illegal drugs. Multiple drug use was frequent; not gender-specific; most common in IDOs 
enacted by young-middle aged individuals, and associated with the consumption of greater 
quantities of tablets in overdose. The ATC classification system enabled the complete 
identification of the involvement of drugs used in IDO and also the identification of specific 
drugs used to treat physical illnesses in IDO. Analgesic, antidepressant, anxiolytic and 
hypnotic and sedative drugs were most commonly consumed in IDO with age, gender, alcohol 
involvement and multiple drug use significantly impacting the frequency of their involvement. 
We found paracetamol to be the most frequently used drug, with a concerning proportion of 
young females overdosing with the drug. 




The demographic profile of persons engaging in IDO identified by the present study is similar 
to that previously described (9, 16, 17). The involvement of alcohol combined with IDO was 
similar to some existing findings (6, 10, 17), particularly in relation to its concentration among 
persons aged 35-54 years (25). However, it was lower than that recently recorded by the 
Multicentre Self-Harm Study (41% vs 58%) (8) and the Northern Ireland Registry of Self-Harm 
(59%) (1). Our findings also quantify and elucidate multiple drug use in IDO, which was more 
frequent than that reported by Finkelstein et al., 2016 in Canada and Vancayseele et al., 2016 
in Belgium (26% and 18%) (9, 17). As expected, multiple drug use was associated with higher 
quantities of tablets taken in overdose, which has been correlated with repeat self-harm and 
an increased risk of suicide (26). Our findings detailing the types of drugs used in IDO build 
upon those reported by Griffin et al., 2014 (1), owing to the application of ATC categorisation 
to our data, facilitating the comprehensive identification of drugs used in IDO. We have also 
described the patterns of drugs used in IDO which are intended to treat physical illnesses. The 
involvement of benzodiazepines in IDO was substantially higher in our study compared to their 
frequency as reported by the Multicentre study (36% versus 14%) (6, 16). This more frequent 
use of benzodiazepines in IDO signals an association between these drugs and high risk of 
self-harm, potentially due to differences in the accessibility of these drugs, the most notable 
and worthy of further research would be disparities in prescribing patterns. Analgesic use in 
IDO in Ireland remains proportionately lower than in England (32.4% vs 45.7%) (16), which is 
potentially impacted by differences in access to paracetamol. In England quantities of 
paracetamol which can be purchased over-the-counter in pharmacy and non-pharmacy 
outlets exceed those available in Ireland (27). Disparities in relation to adherence to sales 
restriction legislation for paracetamol have been reported (28, 29), with comparable research 
into adherence to sales restrictions in pharmacies required. This study too identifies the 
concerning use of paracetamol in IDO, with variations in its involvement determined by gender 
and age, as per previous research (17, 30). 




The findings of this study provide detailed insights into the frequent use of prescription, sale-
restricted and illegal drugs in IDO. We have identified populations at risk of taking prescription 
only drugs in IDO, a finding which can inform prescribing guidelines, in particular to those at 
risk of self-harm. New insights into the involvement of the range of drugs used in IDO highlights 
the need for physicians to also consider risk when prescribing for the management of physical 
illness. In line with evidence-based suicide prevention initiatives, physicians may benefit from 
additional training regarding the frequent use of particular drugs in IDO and measures to 
address issues with prescribing (31, 32). Furthermore, the commonality of multiple drug use 
in our sample and the association between this and repeat self-harm and suicide (26), 
underlines the need to monitor the availability of multiple drug types to individuals, via 
prescription review, particularly to those at risk of self-harm. 
Means restriction has proven efficacy in relation to IDO (27, 32-37) and is increasingly 
recommended by national suicide prevention and drug strategies (38, 39). The frequent use 
of over-the-counter and restricted-sale drugs found in this study accompanied by identified 
issues with adherence to paracetamol sales-restrictions (28, 29) highlight the need to review 
the operations of existing legislation and to examine new ways of preventing individuals, 
particular young people, from accessing excessive quantities of drugs. Considering alcohol, 
the specialised care needs of patients who have engaged in IDO with alcohol will require 
specialist training for hospital staff in the management of these patients (10). 
4.4. Strengths and limitations 
In this study we used robust data from a national self-harm Registry that is internationally 
exclusive to this field. The use of this national dataset with full geographic coverage is unique, 
as endorsed by the World Health Organization (32, 40). The application of the ATC 
classification system (22) to our data is progressive as it has enabled the comprehensive 
examination of specific drugs taken in IDO, previously restricted by unstandardised methods 




comparative work with other drug utilisation statistics and datasets between countries and 
across healthcare settings. There are a number of limitations to this study. Information 
collected on drugs used in IDO was self-reported. Information on the drug dosage and source, 
including whether or not it was prescribed to the individual is not currently collected.  
4.5. Conclusion 
This study presents a comprehensive profile of individuals presenting to hospital following IDO 
with respect to gender, age, alcohol involvement and multiple drug use. The findings raise 
important concerns regarding the use of specific prescribed drugs and patient safety which 
should be considered in prescribing guidelines. The frequent use of over-the-counter drugs 
raises concerns about adherence to and enforcement of legislation regulating the sale of 
certain drugs. The obligation to concurrently and effectively address the specialised care 
needs of IDO patients with alcohol intoxication is reiterated by our findings, requiring address 
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 Frequently used drugs, alcohol and multiple drug use in intentional overdose are 
examined using a national dataset 
 Analgesics, antidepressants, anxiolytics and hypnotic and sedatives are the most 
frequent drug groups taken in overdose 
 Paracetamol is the most common drug taken in overdose, particularly among females 
and those under 25 years 
 Alcohol and multiple drug use are common in overdose, creating specific care needs 
for patients  
 Issues with potential inappropriate prescribing and the enforcement of legislation 
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Table 1 Characteristics of Intentional Drug Overdose (IDO) involvement in self-harm acts, 
2012-2014 
Demographics Male N (%) 
7562 (41.3) 
Female N (%) 
10767 (58.7) 
Total N (%) 
18329  
Age                                 Median (IQR)                                   
                                        <15 years 
                           15-24 
                           25-34 
                           35-44 
                           45-54 






















IDO and self-cutting  549 (7.3) 634 (5.9) 1183 (6.5) 
Alcohol involvement        All ages 
                                        <15 years 
                           15-24 
                           25-34 
                           35-44 
                           45-54 






















Number of drug types     1 drug type 
                                        2 or more  
                                        3 or more  
                                        4 or more  
















Multiple drug use            All ages 
                                       <15 years 
                          15-24 
















                          35-44 
                          45-54 










*Number of tablets       Median (IQR)                                   23 (12,40) 20 (12,35) 20 (12,37) 
*Number of tablets        <10 tablets  
                                      10-19  
                                      20-49  


















Table 2 Therapeutic drug groups involved in IDO according to ATC classification, 2012-2014 
Drug class (ATC) Male N (%) 
N=7562  
Female N (%) 
N=10767  
Total N (%) 
N=18329 
Nervous system (N) 5910 (78.2) 8793 (81.7) 14703 (80.2)* 
Musculoskeletal system (M) 698 (9.2) 1504 (14.0) 2202 (12.0)* 
Illegal drugs 767 (10.1) 335 (3.1) 1102 (6.0)* 
Alimentary tract and metabolism (A) 323 (4.3) 528 (4.9) 851 (4.6) 
Cardiovascular system (C) 278 (3.7) 443 (4.1) 721 (3.9) 
Anti-infective for systemic use (J) 170 (2.2) 367 (3.4) 537 (2.9)* 
Respiratory system (R) 168 (2.2) 361 (3.4) 529 (2.9)* 
Blood and blood forming organs (B) 100 (1.3) 107 (1.0) 207 (1.1) 
Systemic hormonal preparations, excl. sex 
hormones & insulin (S) 
54 (0.7) 133 (1.2) 187 (1.0)* 
Genitourinary system and sex hormones (G) 23 (0.3) 56 (0.5) 79 (0.4) 
Antiparasitic products, insecticides and 
repellents (P) 
18 (0.2) 43 (0.4) 61 (0.3) 
**Antineoplastic and immunomodulating 








*Denotes statistical significance p<0.01. 
**Categories combined due to small numbers.  
For 2005 (10.9%) recorded drugs taken, drug names were recorded at hospital as unknown. 
For 593 (3.2%) of drugs recorded the classification of unknown was attributed to them as it 








Table 3: Nervous system and illegal drugs involved in IDO by gender, age, alcohol and multiple drug use, 2012-2014 
Drug class (ATC) Male N (%) 
N=7562  
Female N (%) 
N=10767  
<25 years   
N (%) 
N=5,618  
25-44 N (%) 
N=8115  
45+ N (%)  
N=4596  






use N (%) 
Nervous system (N) 5910 (78.2) 8793 (81.7) 4332 (77.1) 6592 (81.2) 3779 (82.2)* 14703 (80.2)* 6186 (42.1) 8095 (55.1) 
   Psycholeptics (N05) 3521 (46.6) 4336 (40.3) 1682 (29.9) 3830 (47.2)  2345 (51.0)* 7857 (42.9)* 3568 (45.4) 5185 (66.0) 
     Anxiolytics (N05B) 1832 (24.2) 2062 (19.2) 888 (15.8) 1963 (24.2) 1043 (22.7)* 3894 (21.2)* 1920 (49.3) 2677 (68.7) 
     Hypnotics & sedatives  
     (N05C) 
1610 (21.3) 2248 (20.9) 694 (12.4) 1836 (22.6) 1328 (28.9)* 3858 (21.0) 1736 (45.0) 2765 (71.7) 
     Antipsychotics (N05A) 769 (10.2) 1036 (9.6) 367 (6.5) 927 (11.4) 511 (11.1)* 1805 (9.8) 588 (32.6) 1441 (79.8) 
  Analgesics (N02) 2020 (26.7) 3923 (36.4) 2240 (39.9) 2392 (29.5) 1311 (28.5)* 5943 (32.4)* 2186 (36.8) 3515 (59.1) 
     Other analgesics &  
     antipyretics (N02B) 
1745 (23.1) 3576 (33.2) 2099 (37.4) 2069 (25.5) 1153 (25.1)* 5321 (29.0)* 1931 (36.3) 3082 (57.9) 
     Opioids (N02A) 342 (4.5) 484 (4.5) 206 (3.7) 420 (5.2) 200 (4.4)* 826 (4.5) 335 (40.6) 643 (77.8) 
     Antimigraine preparations  
     (N02C) 
<0.1 <0.1 <0.1 <0.1 <0.1 18 (0.1) (<17.0) 17 (94.4) 
  Psychoanaleptics (N06) 1476 (19.5) 2604 (24.2) 1037 (18.5) 1900 (23.4) 1143 (24.9)* 4080 (22.3)* 1820 (44.6) 2991 (73.3) 




     Psychostimulants, agents  
     used for ADHD and   
     nootropics (N06B) 
34 (0.4) 41 (0.4) 51 (0.9) 17 (0.2) 7 (0.2)* 75 (0.4) 20 (26.7) 44 (58.7) 
     Anti-dementia drugs  
     (N06D) 
5 (0.1) 5 (0.0) 0.1 <0.1 <0.1 10 (0.1) (<20.0) 8 (80.0) 
   Antiepileptics (N03) 642 (8.5) 987 (9.2) 307 (5.5) 834 (10.3) 488 (10.6)* 1629 (8.9) 604 (37.1) 1286 (78.9) 
   Other Nervous System  
   Drugs (N07) 
203 (2.7) 124 (1.2) 79 (1.4) 194 (2.4) 54 (1.2)* 327 (1.8)* 134 (41.0) 265 (81) 
   Anti-Parkinson (N04) 34 (0.4) 33 (0.3) 10 (0.2) 21 (0.3) 36 (0.8)* 67 (0.4) 14 (20.9) 62 (92.5) 
   Anaesthetics (N01) 17 (0.2) 9 (0.1) 13 (0.2) <0.1 <0.1 26 (0.1) 9 (34.6) 17 (65.4) 
   Illegal drugs 767 (10.1) 335 (3.1) 427 (7.6) 630 (7.8) 45 (1.0) 1102 (6.0)* 527 (47.8) 778 (70.6) 
*Denotes statistical significance p<0.01. For 2,005 of drugs taken, drug names were recorded as unknown. For 593 of drugs recorded the 




Table 4 Drugs frequently involved in IDO, by gender and age, 2012-2014 
Drug  Male N (%) 
N=7562 
 
Female N (%) 
N=10767 
<25 years N (%) 
N=5618 
25-44 years N (%) 
N=8115 
45 years+ N (%) 
N=4596 
Total N (%) 
N=18329 
Paracetamols (N02BE01/51) 1644 (21.7) 3443(32.0)* 2034 (36.2) 1996 (24.6) 1057(23.0) 5087 (27.8)* 
Diazepam (N05BA01) 1093 (14.5) 1007 (9.4)* 564 (10.0) 1064 (13.1) 472 (10.3) 2100 (11.5)* 
Zopiclone (N05CF01) 739 (9.8) 953 (8.9) 291 (5.2) 860 (10.6) 541 (11.8) 1692 (9.2)* 
Alprazolam (N05BA12) 583 (7.7) 843 (7.8) 314 (5.6) 713 (8.8) 399 (8.7) 1426 (7.8)* 
Escitalopram (N06AB10) 337 (4.5) 592 (5.5) 275 (4.9) 432 (5.3) 222 (4.8) 929 (5.1) 
Zolpidem (N05CF02) 288 (3.8) 559 (5.2)* 127 (2.3) 397 (4.9) 323 (7.0) 847 (4.6)* 
Pregabalin (N03AX16) 331 (4.4) 470 (4.4) 129 (2.3) 424 (5.2) 248 (5.4) 801 (4.4)* 
Venlafaxine (N06AX16) 206 (2.7) 426 (4.0)* 113 (2.0) 304 (3.7) 215 (4.7) 632 (3.4)* 
Flurazepam (N05CD01) 255 (3.4) 369 (3.4) 111 (2.0) 289 (3.6) 224 (4.9) 624 (3.4)* 
Ibuprofen (M01AE01) 366 (4.8) 846 (7.9)* 529 (9.4) 508 (6.3) 175 (3.8) 1212 (6.6)* 
Diclofenac (M01AB05) 142 (1.9) 290 (2.7)* 159 (2.8) 200 (2.5) 73 (1.6) 432 (2.4)* 
Illegal drugs 767 (10.1) 335 (3.1)* 427 (7.6) 630 (7.8) 45 (1.0) 1102 (6.0)* 
*Denotes statistical significance p<0.01. 
